Feel Breathe, Restriction Device Ventilatory Nasal (COPD) (BreatheCOPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01695265|
Recruitment Status : Completed
First Posted : September 27, 2012
Last Update Posted : June 4, 2018
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Other: Exercie oronasal breathing (ONB) Device: Exercie nasal breathing through the FB||Not Applicable|
Rationale: A device called FeelBreahte (FB)® has been designed, developed and patented for inspiratory muscle training in dynamic situations.
Objetive: To examine the effects of FB on lung ventilation, gas exchange and heart rate during exercise in patients with COPD.
Methods: 20 men with COPD with a forced expiratory volume in the first second between 30% and 70% of its predicted value were selected. In the first visit to the laboratory, baseline static maximum inspiratory pressure and spirometry were performed previous to the exercise. Then, a maximal incremental cardiopulmonary exercise test was performed to determine ventilatory and cardiac parameters. During the second day, each participant conducted two tests with 30 min of rest between them. Exercise protocol was an identical walk on a treadmill for 10 minutes at a constant rate at 50% of VO2peak. Each test was performed randomnly in two different conditions: 1) oronasal breathing (ONB); and 2) nasal breathing through the FB.
Results: Lung ventilation and gas exchange during exercise in COPD patients was modified during exercise using FB. Our results showed a positive effects of FB vs ONB on dynamic hyperinflation, an improved breathing pattern and breathing efficiency, higher expiratory and inspiratory time and higher perceived effort. Despite these differences, blood oxygen saturation percentage, oxygen uptake and heart rate showed similar response between both conditions.
Conclusions: The new device FB used during exercise in COPD patients influenced ventilatory responses to an efficiency breathing compared to oronasal mode.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Feel Breathe, Restriction Device Ventilatory Nasal (COPD)|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||September 2015|
Experimental: Exercie oronasal breathing (ONB)
Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with oronasal breathing (ONB) (Without FeelBreathe device)
Other: Exercie oronasal breathing (ONB)
10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
Experimental: Exercie nasal breathing through the FB
Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with nasal restriction using FeelBreathe device.
Device: Exercie nasal breathing through the FB
Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
- Overall impact of a restriction device ventilatory nasal over different physiological variables in COPD [ Time Frame: Subjects were assessed during 8 weeks ]The investigators measure minute ventilation, peak oxygen uptake (VO2p), peak carbon dioxide production (VCO2p), breathing frequency (BF), ventilatory equivalent for carbon dioxide (CO2 Eq), ventilatory equivalent for oxygen (Eq O2), expiratory tidal volume (Vtexp), inspiratory tidal volume (Vtins), end-tidal carbon dioxide tension (PETCO2), end-tidal oxygen tension (PETO2), inspiratory time (T.in), ratio of inspiratory duration to total breath duration (ti/t), expiratory time (Tex), oxygen saturation measure by pulse-oximetry SpO2), heart rate (HR), duration of the test and dyspnea and leg fatigue measures by Borg scale. Each subject performed two identical submaximal exercises at 50% of VO2peak under different breathing conditions: 1) nasal breathing with FB and 2) oronasal breathing without FB. Incremental exercise tests were performed on a treadmill ergometer using a one minute step protocol to a symptom-limited maximum.
- Maximal Oxygen uptake [ Time Frame: Subjects were assessed during 8 weeks ]Before experimental trials each subject performed an incremental protocol on a treadmill ergometer (MONARK, Hamburg, Germany) for the determination of gas exchange. The test was stopped upon volitional fatigue of the subject. Gas-exchange data were measured breath by breath using an Oxycon cardiopulmonary exercise system (Jaeger, Hoechberg, Germany).
- Maximum static inspiratory pressure (PImax) [ Time Frame: Subjects were assessed during 8 weeks ]Inspiratory muscle testing was performed using a mouth pressure meter (Micro Medical Inc., Chatham, Kent, UK). The manufacturer states that the test-retest reliability of this device is ±3%. PImax was measured at residual volume and the best result from three inspiratory attempts was taken. Al least one minute was allowed between attempts to minimize the effects of muscle fatigue.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01695265
|Centro Andaluz Medicina del Deporte|
|San Fernándo, Cádiz, Spain, 11100|
|Study Director:||Aurelio Arnedillo Muñoz, PhD||Hospital Puerta del Mar Cádiz Spain|
|Study Director:||Carmen Vaz Pardal, MD||Centro de Medicina del Deporte. Junta de Andalucía. Cádiz|
|Study Director:||Jose Lopez Chicharro, PhD||Universidad Autonoma de Madrid|
|Study Chair:||Pelayo Arroyo García, PhD||University of Cadiz|
|Study Director:||Jose Castro Piñero, PhD||University of Cadiz|
|Study Chair:||Jorge dR Fernández Santos, PhD Student||University of Cadiz|
|Study Chair:||Davinia Vicente Campos, PhD||Universidad Complutense de Madrid|
|Principal Investigator:||José L. González Montesinos, PhD||University of Cadiz|
|Study Chair:||Julio Conde Caveda, PhD||University of Cadiz|
|Study Director:||Jesús G Ponce González, PhD||University of Cadiz|